FDA
-
-
-
-
-
-
-
Ambulatory Surgery Center Completes WATER IV Trial Procedures for Prostate Cancer with Aquablation® Therapy
-
-
-
-
-
-
-
Procept BioRobotics Corp (PRCT) PT Raised to $94 at BofA Securities
-
-
-
-
-
-
-
The National Institute for Health and Care Excellence Endorses Aquablation® Therapy with "Standard Arrangements" Recommendation
-
-
-
-
-
-
-
Five-Year Data from the WATER II Study Demonstrate Aquablation Therapy Delivers Significant Durable Improvement of Benign Prostatic Hyperplasia Symptoms while Preserving Sexual Function in Men with La
-
-
-
-
-
-
-
PROCEPT Announces 5-Year WATER Study Data Comparing Aquablation to TURP
-
327,748 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

